Recently, a meta-analysis of randomised trials that compared PDE5 inhibition with placebo in chronic heart failure showed that effects of PDE5 inhibition in patients with HFpEF were heterogeneous, and the beneficial effect of PDE5 inhibition was related to the baseline PAP as well as the extent of PDE5 inhibition–mediated PAP decrease [24]. Here, PDE5A is linked to congestive heart failure.